National Agri-Food Biotechnology Institute, Sector-81 Mohali, Sahibzada Ajit Singh Nagar 140306, Punjab, India.
Department of Biotechnology, Panjab University Chandigarh, Sector 25, Chandigarh 160014, Punjab, India.
ACS Appl Bio Mater. 2021 Oct 18;4(10):7467-7484. doi: 10.1021/acsabm.1c00720. Epub 2021 Sep 28.
Iron deficiency anemia (IDA) is the most common nutritional disorder worldwide nearly affecting two billion people. The efficacies of conventional oral iron supplements are mixed, intravenous iron administration acquaintances with finite but crucial risks. Usually, only 5-20% iron is absorbed in the duodenum while the remaining fraction reaches the colon, affecting the gut microbes and can significantly impact intestinal inflammatory responses. Therefore, administration of gut bacterial modulators such as probiotics, prebiotics, and any other dietary molecules that can stimulate healthy gut bacteria can enhance iron absorption without any adverse side effects. In this study, we have prepared an iron supplement to avoid the side effects of conventional oral iron supplements. The formulation includes co-encapsulation of iron with anti-inflammatory probiotic bacteria within alginate/starch hydrogels (B + I-Dex (H)), which has been demonstrated to be efficient in mitigating IDA . As intestinal pH increases, the pore size of hydrogel increases due to ionic interactions and thus releases the encapsulated bacteria and iron. The field emission scanning electron microscopy (FESEM) analysis confirmed the porous structure of hydrogel beads, and release studies showed a sustained release of iron and bacteria at intestinal pH. The hydrogel was found to be nontoxic and biocompatible in Caco2 cell lines. The formulation showed efficient and iron bioavailability in Fe depletion-repletion studies. B + I-Dex (H) was observed to generate less inflammatory response than FeSO or nonencapsulated iron dextran (I-Dex) . We entrust that this duly functional hydrogel formulation could be further utilized or modified for the development of oral therapeutics for IDA.
缺铁性贫血(IDA)是全球最常见的营养失调症,几乎影响了 20 亿人。传统口服铁补充剂的疗效参差不齐,而静脉内铁给药则存在有限但关键的风险。通常,十二指肠仅能吸收 5-20%的铁,其余部分到达结肠,影响肠道微生物群,并可能对肠道炎症反应产生重大影响。因此,给予肠道细菌调节剂,如益生菌、益生元及任何其他可刺激健康肠道细菌的饮食分子,可在无任何不良反应的情况下增强铁吸收。在这项研究中,我们制备了一种铁补充剂以避免传统口服铁补充剂的副作用。该配方包括将铁与抗炎益生菌共同包封于藻酸盐/淀粉水凝胶内(B + I-Dex(H)),已证实其在缓解 IDA 方面有效。随着肠道 pH 值的增加,由于离子相互作用,水凝胶的孔径增大,从而释放出包封的细菌和铁。场发射扫描电子显微镜(FESEM)分析证实了水凝胶珠的多孔结构,释放研究表明在肠道 pH 值下铁和细菌的释放具有持续性。水凝胶在 Caco2 细胞系中被发现是无毒且生物相容的。该配方在铁耗竭-补充研究中显示出高效和高的铁生物利用度。与 FeSO 或未包封的铁葡聚糖(I-Dex)相比,B + I-Dex(H)观察到产生的炎症反应更少。我们相信,这种功能齐全的水凝胶配方可进一步用于或修改,以开发用于 IDA 的口服治疗药物。